RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist.
Increased synthesis of Apolipoprotein A-I (ApoA-I) and HDL is believed to provide a new approach to treating atherosclerosis through the stimulation of reverse cholesterol transport. RVX-208 increases the production of ApoA-I in hepatocytes in vitro, and in vivo in monkeys and humans, which results...
Guardado en:
Autores principales: | Kevin G McLure, Emily M Gesner, Laura Tsujikawa, Olesya A Kharenko, Sarah Attwell, Eric Campeau, Sylwia Wasiak, Adam Stein, Andre White, Eric Fontano, Robert K Suto, Norman C W Wong, Gregory S Wagner, Henrik C Hansen, Peter R Young |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2013
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e475fa058c6c480b97460e96177ac8f4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations
por: Qianqian Wang, et al.
Publicado: (2017) -
Selective BET bromodomain inhibition as an antifungal therapeutic strategy
por: Flore Mietton, et al.
Publicado: (2017) -
BRD3 and BRD4 BET Bromodomain Proteins Differentially Regulate Skeletal Myogenesis
por: Thomas C. Roberts, et al.
Publicado: (2017) -
HDL-apoA-I exchange: rapid detection and association with atherosclerosis.
por: Mark S Borja, et al.
Publicado: (2013) -
Genome-wide CRISPR-Cas9 screens identify mechanisms of BET bromodomain inhibitor sensitivity
por: David Estoppey, et al.
Publicado: (2021)